Morbidity Associated With Primary Hyperparathyroidism-A Population-based Study With a Subanalysis on Vitamin D

被引:4
作者
Soto-Pedre, Enrique [1 ,2 ]
Lin, Yeun Yi [3 ,4 ]
Soto-Hernaez, Jimena [5 ,7 ]
Newey, Paul J. [3 ,4 ,6 ]
Leese, Graham P. [1 ,2 ,3 ,4 ]
机构
[1] Univ Dundee, Ninewells Hosp, Sch Med, Div Populat Hlth & Genom, Level 5,Mailbox 12, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Med Sch, Level 5,Mailbox 12, Dundee DD1 9SY, Scotland
[3] Univ Dundee, Ninewells Hosp, Dept Endocrinol & Diabet, Dundee DD1 9SY, Scotland
[4] Univ Dundee, Med Sch, Dundee DD1, Scotland
[5] Univ Bristol, Sch Med, Bristol BS8 1QU, England
[6] Univ Dundee, Ninewells Hosp, Sch Med, Div Mol & Clin Med, Dundee DD1 9SY, Scotland
[7] Univ Dundee, Med Sch, Dundee DD1 9SY, Scotland
关键词
primary hyperparathyroidism; vitamin D; calcium; mortality; PARATHYROID EPIDEMIOLOGY; AUDIT RESEARCH; MORTALITY; SURGERY; DISEASE;
D O I
10.1210/clinem/dgad103
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Primary hyperparathyroidism (PHPT) is associated with increased risk of morbidity and death, and vitamin D levels are a potentially confounding variable. Objective The aim of this study was to assess morbidity and mortality associated with primary hyperparathyroidism (PHPT). Methods In this population-based retrospective matched cohort study, data linkage of biochemistry, hospital admissions, prescribing, imaging, pathology, and deaths was used to identify patients across the region of Tayside, Scotland, who had PHPT from 1997 to 2019. Cox proportional hazards models and hazards ratios (HR) were used to explore the relationship between exposure to PHPT and several clinical outcomes. Comparisons were made with an age- and gender-matched cohort. Results In 11 616 people with PHPT (66.8% female), with a mean follow-up period of 8.8 years, there was an adjusted HR of death of 2.05 (95% CI, 1.97-2.13) for those exposed to PHPT. There was also an increased risk of cardiovascular disease (HR = 1.34; 95% CI, 1.24-1.45), cerebrovascular disease (HR = 1.29; 95% CI, 1.15-1.45), diabetes (HR = 1.39; 95% CI, 1.26-1.54), renal stones (HR = 3.02; 95% CI, 2.19-4.17) and osteoporosis (HR = 1.31; 95% CI, 1.16-1.49). Following adjustment for serum vitamin D concentrations (n = 2748), increased risks for death, diabetes, renal stones, and osteoporosis persisted, but not for cardiovascular or cerebrovascular disease. Conclusion In a large population-based study, PHPT was associated with death, diabetes, renal stones, and osteoporosis, independent of serum vitamin D concentration.
引用
收藏
页码:E842 / E849
页数:8
相关论文
共 38 条
[1]   Analysis of Comorbidities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyroidism [J].
Axelsson, Kristian F. ;
Wallander, Marit ;
Johansson, Helena ;
Harvey, Nicholas C. ;
Vandenput, Liesbeth ;
McCloskey, Eugene ;
Liu, Enwu ;
Kanis, John A. ;
Litsne, Henrik ;
Lorentzon, Mattias .
JAMA NETWORK OPEN, 2022, 5 (06)
[2]   Meta-analysis on the Effect of Mild Primary Hyperparathyroidism and Parathyroidectomy Upon Arterial Stiffness [J].
Bernardi, Stella ;
Giudici, Fabiola ;
Barbato, Vincenzo ;
Zanatta, Lorenzo ;
Grillo, Andrea ;
Fabris, Bruno .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (06) :1832-1843
[3]   Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism [J].
Beysel, Selvihan ;
Caliskan, Mustafa ;
Kizilgul, Muhammed ;
Apaydin, Mahmut ;
Kan, Seyfullah ;
Ozbek, Mustafa ;
Cakal, Erman .
BMC CARDIOVASCULAR DISORDERS, 2019, 19 (1)
[4]   Primary hyperparathyroidism: insights from the Indian PHPT registry [J].
Bhadada, Sanjay Kumar ;
Arya, Ashutosh Kumar ;
Mukhopadhyay, Satinath ;
Khadgawat, Rajesh ;
Sukumar, Suja ;
Lodha, Sailesh ;
Singh, Deependra N. ;
Sathya, Anjali ;
Singh, Priyanka ;
Bhansali, Anil .
JOURNAL OF BONE AND MINERAL METABOLISM, 2018, 36 (02) :238-245
[5]   The Fifth International Workshop on the Evaluation and Management of Primary Hyperparathyroidism [J].
Bilezikian, John P. ;
Khan, Aliya A. ;
Clarke, Bart L. ;
Mannstadt, Michael ;
Potts, John T. ;
Brandi, Maria Luisa .
JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (11) :2290-2292
[6]   Primary Hyperparathyroidism [J].
Bilezikian, John P. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (11) :3993-4004
[7]   Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop [J].
Bilezikian, John P. ;
Brandi, Maria Luisa ;
Eastell, Richard ;
Silverberg, Shonni J. ;
Udelsman, Robert ;
Marcocci, Claudio ;
Potts, John T., Jr. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (10) :3561-3569
[8]   Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT) [J].
Bollerslev, Jens ;
Schalin-Jantti, Camilla ;
Rejnmark, Lars ;
Siggelkow, Heide ;
Morreau, Hans ;
Thakker, Rajesh ;
Sitges-Serra, Antonio ;
Cetani, Filomena ;
Marcocci, Claudio ;
Guistina, Andrea ;
Van Hul, Wim ;
Amrein, Karin ;
Sikjaer, Tanja ;
Hindle, Elif ;
Vamvalddis, Kyriakos ;
Corbetta, Sabrina ;
Balaia, Zhanna ;
Astor, Marianne ;
Makay, Ozer ;
Newey, Paul ;
Hannan, Fadil ;
Rolighed, Lars ;
Appelman-Dijkstra, Natasha ;
Wicke, Corrina ;
Pilz, Stefan ;
Saponaro, Federica ;
Vestergard, Peter .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (03) :P1-P19
[9]   Effect of Surgery on Cardiovascular Risk Factors in Mild Primary Hyperparathyroidism [J].
Bollerslev, Jens ;
Rosen, Thord ;
Mollerup, Charlotte L. ;
Nordenstroem, Joergen ;
Baranowski, Marek ;
Franco, Celina ;
Pernow, Ylva ;
Isaksen, Gunhild A. ;
Godang, Kristin ;
Ueland, Thor ;
Jansson, Svante .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (07) :2255-2261
[10]   The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies [J].
Chandran, Manju ;
Bilezikian, John P. ;
Lau, Joel ;
Rajeev, Reshma ;
Yang, Samantha Peiling ;
Samuel, Miny ;
Parameswaran, Rajeev .
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2022, 23 (03) :485-501